ResMed Inc. (NYSE:RMD) announced a quarterly dividend on Thursday, October 24th, RTT News reports. Shareholders of record on Thursday, November 7th will be given a dividend of 0.39 per share by the medical equipment provider on Thursday, December 12th. This represents a $1.56 dividend on an annualized basis and a yield of 1.22%.
Shares of NYSE:RMD traded up $0.99 during trading on Thursday, reaching $127.73. The stock had a trading volume of 521,130 shares, compared to its average volume of 742,143. The firm’s fifty day moving average is $133.10 and its 200 day moving average is $122.50. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.43 and a current ratio of 2.06. ResMed has a 52 week low of $90.64 and a 52 week high of $141.25. The stock has a market cap of $18.19 billion, a price-to-earnings ratio of 35.09, a P/E/G ratio of 3.04 and a beta of 0.41.
ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $0.95 EPS for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.03. ResMed had a net margin of 15.52% and a return on equity of 26.49%. The company had revenue of $705.00 million for the quarter, compared to analyst estimates of $701.56 million. During the same period in the prior year, the firm posted $0.95 EPS. The company’s quarterly revenue was up 13.1% on a year-over-year basis. On average, research analysts forecast that ResMed will post 3.93 earnings per share for the current fiscal year.
A number of equities research analysts have recently commented on the stock. UBS Group raised shares of ResMed from a “neutral” rating to a “buy” rating and upped their price objective for the company from $122.00 to $140.00 in a research note on Monday, July 29th. Zacks Investment Research raised shares of ResMed from a “hold” rating to a “buy” rating and set a $131.00 price objective on the stock in a research note on Monday, July 8th. ValuEngine lowered shares of ResMed from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Goldman Sachs Group raised shares of ResMed from a “neutral” rating to a “buy” rating in a research note on Monday, July 29th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research note on Friday, October 18th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $121.50.
ResMed Company Profile
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Recommended Story: Book Value Per Share – BVPS
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.